Get started
Author

Luisa Castellana

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials
2019 · Antonio Galvano, Dalila Scaturro, et al. · Journal of bone oncology · 38
PDF
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
2022 · Antonio Galvano, Luisa Castellana, et al. · Therapeutic Advances in Medical Oncology · 25
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
2022 · Valerio Gristina, Nadia Barraco, et al. · Cancers · 24
PDF
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
2021 · Valerio Gristina, Maria La Mantia, et al. · Journal of Molecular Pathology · 24
PDF
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
2018 · Angela Listì, Nadia Barraco, et al. · Translational Cancer Research · 21
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
2021 · Valerio Gristina, Antonio Galvano, et al. · Therapeutic Advances in Medical Oncology · 18
Laparoscopic Approach for Thermoablation Microwave in the Treatment of Hepatocellular Carcinoma: A Single Center Experience
2016 · Salvatore Gruttadauria, Duilio Pagano, et al. · Journal of Laparoendoscopic & Advanced Surgical Techniques · 16
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study
2025 · L. Incorvaia, C. Marchetti, et al. · ESMO Open · 13
PDF
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials
2019 · Daniele Santini, Antonio Galvano, et al. · Critical Reviews in Oncology/Hematology · 8
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
2019 · Antonio Galvano, Lorena Incorvaia, et al. · Cancers · 6
PDF
Opioids in advanced cancer: use, storage and disposal in the home
2022 · Sebastiano Mercadante, Lucia Adamoli, et al. · BMJ Supportive & Palliative Care · 3
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
2023 · Lorena Incorvaia, Chiara Brando, et al. · Journal of Clinical Oncology · 2
P07.02 Detection of Molecular Residual Disease (MRD) using ctDNA in NSCLC: A Systematic Review and Meta-Analysis
2021 · A. Galvano, V. Gristina, et al. · Journal of Thoracic Oncology · 2
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?
2019 · Daniele Fanale, Lorena Incorvaia, et al. · Journal of Clinical Oncology · 2
20P Is evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutational status on circulating tumour DNA (ctDNA) by liquid biopsy ready for prime-time? A systematic review and an individual patient meta-analysis
2021 · L. Castellana, V. Gristina, et al. · Annals of Oncology · 1
1582P Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
2024 · L. Incorvaia, T.D. Bazan Russo, et al. · Annals of Oncology
PDF
1221P The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
2023 · L. Incorvaia, C. Marchetti, et al. · Annals of Oncology
PDF
EP16.01-013 The Diagnostic Accuracy of Tumor Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis
2022 · M. La Mantia, V. Gristina, et al. · Journal of Thoracic Oncology
1094P The clinical potential of circulating-free DNA (cfDNA) for real-time longitudinally monitoring clinical outcomes in a real-world first-line non-small cell lung cancer (NSCLC) prospective study
2022 · V. Gristina, N. Barraco, et al. · Annals of Oncology
1818P Body mass index (BMI) is not a cancer risk factor for BRCA1/2 carriers: A systematic review and meta-analysis of case-control studies
2021 · V. Gristina, A. Galvano, et al. · Annals of Oncology
Body Mass Index (BMI) is not a cancer risk factor for BRCA1/2 carriers: a Systematic Review and Meta-analysis of case-control studies
2021 · Mario Giuseppe Mirisola, Antonio Galvano, et al. · Research Square
PDF
P33.15 TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors
2021 · V. Gristina, A. Galvano, et al. · Journal of Thoracic Oncology
PDF
P48.10 Chemo-Immunotherapy in the Frontline of Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Indirect Comparisons
2021 · A. Galvano, V. Gristina, et al. · Journal of Thoracic Oncology
PDF
Endometrial and Cervical Cancers
2021 · Lorena Incorvaia, Luisa Castellana, et al. · UNIPA Springer series
1281P The prognostic impact of tissue tumour mutational burden (TMB) in the first-line treatment of advanced non-oncogene addicted non-small cell lung cancer (NSCLC): A systematic review and meta-analysis of randomized controlled trials
2020 · V. Gristina, A. Galvano, et al. · Annals of Oncology
Works count: 54
Citation count: 203
H-index: 8
I10-index: 8
Year
Topic
Type